1 / 30

INTRALIPIDS AS RESCUE

INTRALIPIDS AS RESCUE. 2:30-3:30. Objectives. Describe signs and symptoms of local anesthetic (LA) toxicity. Identify treatment modalities including use of lipids for patients with LA toxicity. Identify factors influencing LA toxicity. Mechanism of action. Loss of sensation by

ivo
Télécharger la présentation

INTRALIPIDS AS RESCUE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. INTRALIPIDS AS RESCUE 2:30-3:30

  2. Objectives • Describe signs and symptoms of local anesthetic (LA) toxicity. • Identify treatment modalities including use of lipids for patients with LA toxicity. • Identify factors influencing LA toxicity.

  3. Mechanism of action Loss of sensation by inhibiting excitation at nerve endings blocking conduction in peripheral nerves Progression of anesthesia related to affected nerve fiber: diameter myelination conduction velocity Prevent the development of action potential in nerve

  4. Regional Anesthesia Involves the use of a local anesthetic strategically placed along the neural access to produce: Surgical anesthesia Postoperative analgesia Analgesia for acute & chronic pain management Goal: Block conduction of nociceptive (pain) impulses

  5. LOCAL AGENTS • Levels dependent on: • Dose • Rate of injection • Specific gravity of fluid • Position of patient

  6. LOCAL AGENTS • ESTERS • Hydrolyzed in Plasma • Unstable in solution • Poor Penetrance • Fair to Poor Stability • EXAMPLES • Cocaine – (1884) • Procaine - (Novacain) – 1984 • Chloroprocaine - (Nesacaine) • Tetracaine- (Pontocaine) - 1931

  7. LOCAL AGENTS AMIDES Metabolized by Liver Stable Good Penetrance Lidocaine - (Xylocaine) Mepivacaine - (Carbocaine) Prilocaine - (Citanest) Bupivacaine - (Marcaine, Sensorcaine) Etidocaine Ropivacaine

  8. LOCAL AGENTS Epinepherine Added to Local Vasoconstriction Slows Vascular Absorption Prolongs Effect

  9. Local Anesthesia Toxicity • Agents used in excessive doses or administered improperly. • Repetitive (small) doses to achieve an adequate level of anesthesia may lead to eventual administration of toxic dose. • Anesthesia injected into confined space • Doses may inadvertently be delivered as intravascular injection rather than epidurally

  10. Local Anesthesia Toxicity • Administration of toxic doses of LA • Increase disruptions of cellular metabolism • Interfere with inotropic function pathways that regulate NA+, K+ and Cl- ion flow • Modulation of autonomic system and enzymatic processes for ATP formation

  11. Toxicity • Early: agitation, lightheadedness, altered mental state, visual changes, slurred speech, hypertension and tachycardia • Middle: CNS excitation, cardiac dysrhythmias, contractile depression & conduction blockade. Seizure ( 20-30 minutes) • Severe: Hypotension, bradycardia, Ventricular dysrhythmia and cardiovascular collapse

  12. CNS Toxicity • Sedation • CNS excitation at low drug concentration • Dizziness, ringing in the ear, Metallic taste • Paresthesia (circumoral tingling) • Anxiety • Fear of death • Uncontrolled muscle activity • Tonic –clonic seizures • CNS depression • Bupivacaine ( CNS & Cardiac toxicity simultaneously

  13. Cardiovascular Toxicity • Block of sodium, calcium and potassium channels • Difficult to resuscitate on patient with asystole with Bupivacaine toxicity due to long term • Bupivacaine is cardiotoxic, strong attraction to myocardial sodium channel, slow dissociation from the sodium channels due to its lipophilic properties.

  14. Management of Local Anesthesia Toxicity • ACLS protocol • Airway • Vital Signs • Resuscitative Medications

  15. Chance Observation • Noted that patient with carnitine deficiency exhibited sensitivity to bupivacaine induced cardiac dysrhythnias, therefore postulated that bupivacaine might interfere with carnitine metabolism. • Carnitine = essential component of biochemical pathways that transport fatty acids into mitochondria where they provide the majority of cardiac energy needs. • Interestingly enough, the opposite was discovered – infusing lipids made them more resistant to bupivacaine-induced asystole. • Lipid infusion improves the success of resuscitation from bupivacaine toxicity.

  16. 2006 Case • 17 year old developed seizure activity and CV collapse after intentional ingestion. • Ingested: Bupropion (Antidepressant) and Lamotrigine (Anticonvulsant) • Unsuccessful resuscitation attempts for 70 minutes • 100 ml IV bolus of 20% lipid emulsion given • After 1 minute, an effective sustained pulse was observed. Patient recovered with no major neurologic deficit.

  17. 91 year oldHistory: COPD, HTN, CAD, Reflux • Infraclavicular brachial plexus block for olecranon bursa excision. • Given 1% mepivicaine 30 ml • 20 min after injection was then injected with 10 ml 1% Prilocaine. • 5 minutes after injection of prilocaine, (20 min after patient received the Mepivicaine) patient developed dizziness, nausea, agitation & then lost consciousness • Given 1ml/kg bolus of 20% intralipid followed by infusion and patient recovered within minutes and surgery proceeded.

  18. 60 year old male with CAD, diabetes and end-stage renal disease • For Supraclavicular Brachial plexus block he received: • 30 ml 1.5% mepivacaine with bicarbonate and epi • 10 ml 0.5% bupivacaine • Developed labored respiration followed by obtundation 5 min after injection • CPR without re-establishment of effective cardiac rhythm • Given 20% lipid (250 ml over 30 min) patient recovered

  19. Local Anesthetic Systemic Toxicity (LAST) requiring treatment • 20 out of 10,000 peripheral nerve blocks • 4 out of 10,000 epidural blocks • Initial symptoms of LA Overdose • Mild hypertension • Tachycardia • Mild agitation • Confusion

  20. Cardiac Toxicity • Hypotension • Atrioventricular conduction delay • Idioventricular rhythms • Respiratory depression • Cardiovascular collapse

  21. Local Anesthetic Toxicity • Can occur after ingestion • IV administration • Topical Administration

  22. Checklist for Treatment of LAST(ASRA & Pain Medicine) • Get Help • Initial focus • Airway management • Seizure suppression ( Benzodiazepines NOT Propofol) • Alert nearest facility having Cardiopulmonary bypass capability • Manage cardiac dysrhymias • BLS & ACLS • Avoid Vasopressin, Calcium channel blockers, beta blockers and local anesthetics • Reduce epinepherine doses to <1mcg/kg

  23. Checklist for Treatment of LAST(ASRA & Pain Medicine) • Lipid emulsion therapy (20%) • Bolus 1.5 ml/kg IV over 1 minute • Continuous infusion 0.25 ml/kg/min • Repeat bolus once or twice for persistent CV collapse • Double the infusion rate to 0.5 ml/kg/min if BP low • Continue infusion for at least 10 min after attaining circulatory stability • Recommend upper limit: 10ml/kg/lipid emulsion over 30 min. • Post LAST events at www.lipidrescue.org or www.lipidregistry.org

  24. Lipid Sink • Expanded plasma lipid compartment that traps lipophilic drugs • Infused intravascular lipid mass binds the offending toxin in sufficient quantity to pull drug from the target tissue, thereby reversing the toxicity. • Successful resuscitation suggest the efficacy of lipid emulsion infusion for treating non-local anesthetic overdoses across a wide spectrum of drugs: beta blockers, calcium channel blockers, parasiticides, herbicides and several varieties of psychotropic agents.

  25. 2 Proposed methods of How Intralipids Work • 1. Lipid infusion creates a lipid phase in the plasma to which local anesthetics partition into. • 2. Reversal of mitochondrial fatty acid transport inhibition • Believed LA inhibit carnitineacylcarnitinetranslocase (CACT) – an enzyme used in mitochrondrial fatty acid metabolism and transport • Because fatty acids are involved in 80-90% of cardiac adenosine 5-triphosphate (ATP) synthesis, inhibition of CACT may contribute to cardiac toxicity. • Lipid infusion may increase the intracellular fatty acid content enough to overcome the inhibition of the CACT enzyme by the anesthetic.

  26. Death of woman at a Laser Treatment Center • Patient received cream containing 10% Lidocaine and 10% Tetracaine. • Patient applied cream over Large areas of skin then wrapped her legs in cellophane which increased the absorption of the drug. • Found seizing in her car. • Unable to resuscitate

  27. Lipid Therapy Side Effect • Allergic reaction, headache, somnolence, dizziness, dyspnea, diaphoresis, N&V, hyperthermia and hypercoagulability • Thrombocytopenia, jaundice, overloading syndrome, Increased liver function, leucopenia, hepatomegaly, splenomegaly • Pulmonary hypertension with long term therapy • Yeast infection

  28. Conclusions • Lipid infusion appears to reverse cardiotoxicity rapidly and is easier than cardiopulmonary bypass. • Lipid emulsion is readily available at a much lower cost. • Lipid rescue therapy is to be reserved until ACLS procedures have been unsuccessful in cases of local anesthetic toxicity

  29. Summary • Nurses plan an important role towards a successful outcome for patients with local anesthesia toxicity • Know your high risk patients • Recognize signs and symptoms of toxicity • Have adequate emergency equipment available when resuscitation needs arise • Know your facility policy for Local Anesthesia Toxicity

More Related